Citigroup Lowers Caris Life Sciences (NASDAQ:CAI) Price Target to $28.00

Key Points

• Citigroup cut its price target on Caris Life Sciences from $35 to $28 while keeping a buy rating, implying about 73% upside from the previous close.
• Analyst sentiment remains mixed but generally positive: the stock carries a Moderate Buy consensus, with six Buy ratings, two Holds, and one Sell, and an average target price of $27.56.
• Caris shares fell to $16.15 on Friday as the company continues to trade well below its 52-week high, even after reporting strong quarterly results with revenue up 125.4% year over year.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) had its price objective cut by equities researchers at Citigroup from $35.00 to $28.00 in a research report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's price objective would indicate a potential upside of 73.37% from the company's previous close.

Several other research analysts have also weighed in on CAI. Wall Street Zen lowered shares of Caris Life Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. The Goldman Sachs Group started coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They issued a "buy" rating and a $27.00 price objective on the stock. BTIG Research decreased their target price on shares of Caris Life Sciences from $38.00 to $32.00 and set a "buy" rating for the company in a research report on Friday. Canaccord Genuity Group decreased their target price on shares of Caris Life Sciences from $30.00 to $22.00 and set a "hold" rating for the company in a research report on Friday, March 13th. Finally, Piper Sandler started coverage on shares of Caris Life Sciences in a research report on Friday, April 10th. They issued a "neutral" rating and a $21.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Caris Life Sciences has a consensus rating of "Moderate Buy" and an average target price of $27.56.

Caris Life Sciences Price Performance

Caris Life Sciences stock traded down $3.69 during trading hours on Friday, hitting $16.15. The company had a trading volume of 8,860,972 shares, compared to its average volume of 2,445,794. The firm has a market capitalization of $4.56 billion and a price-to-earnings ratio of -89.72. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66. The company's fifty day moving average is $19.15. Caris Life Sciences has a fifty-two week low of $15.71 and a fifty-two week high of $42.50.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. The firm's quarterly revenue was up 125.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.73) EPS. Analysts anticipate that Caris Life Sciences will post 0.12 earnings per share for the current year.

Institutional Trading of Caris Life Sciences

Large investors have recently modified their holdings of the company. UBS Group AG boosted its holdings in shares of Caris Life Sciences by 825.9% during the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company's stock worth $58,924,000 after buying an additional 1,948,107 shares during the period. Zevenbergen Capital Investments LLC bought a new stake in shares of Caris Life Sciences during the 4th quarter worth $14,655,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Caris Life Sciences during the 4th quarter worth $3,942,000. Hamilton Lane Advisors LLC bought a new stake in shares of Caris Life Sciences during the 4th quarter worth $1,584,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Caris Life Sciences in the 4th quarter valued at $2,498,000.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q1 results showed strong top‑line growth — Caris reported total revenue of $216.2M, up 79% year‑over‑year, driven by molecular profiling services, which supports the company’s growth thesis. PR Newswire — Q1 Results
• Positive Sentiment: Management’s earnings call was characterized by some observers as signaling a “profitable surge,” reinforcing that revenue growth is translating toward better profitability metrics — a constructive fundamental datapoint for investors. TipRanks — Earnings Call Highlights
• Neutral Sentiment: Full Q1 earnings call transcript and presentation are available for investors who want the details (useful for modeling and verifying management commentary). Seeking Alpha — Q1 Earnings Transcript Seeking Alpha — Presentation
• Neutral Sentiment: Company updated FY‑2026 guidance at the call, but the published entry contains garbled figures; investors are parsing management’s guide for clarity — ambiguous guidance often increases short‑term volatility.
• Negative Sentiment: JPMorgan cut its price target from $35 to $30 (maintaining an Overweight rating). The downgrade in target reduces near‑term sentiment even though the target still implies significant upside vs. the current price. Benzinga — JPMorgan PT Cut TickerReport — JPMorgan
• Negative Sentiment: BTIG trimmed its price target from $38 to $32 (still a Buy). Another analyst PT cut compounds selling pressure despite the retained positive ratings. Benzinga — BTIG PT Cut The Fly — BTIG

Caris Life Sciences Company Profile

Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.